Flow cytometry analysis with a new FITC-conjugated monoclonal antibody-3E12 for HLA-B*57:01 rapid screening in prevention of abacavir hypersensitivity in HIV-1-infected patients

HIV Clinical Trials

Volumn 14, Issue 4, 2013, Pages 160-164

  Rodriguez Sainz C ^a   Valor, L ^a   Hernandez D ^a   Gil, J ^a   Carbone, J ^a   Pascual Bernaldez, M ^b   Rodriguez Alcantara F ^c   Martinez I ^a   Vicario, J ^d   Mallal, S ^e   Fernandez Cruz E ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b GLAXOSMITHKLINE   (Spain)

^c VIIV HEALTHCARE   (United States)

^d Centro de Transfusión de la Comunidad de Madrid ^*  (Spain)

^e MURDOCH UNIVERSITY   (Australia)

Author keywords

abacavir; DNA PCR technique; drug hypersensitivity; flow cytometry; HLA B*57:01

Indexed keywords

ABACAVIR; FLUORESCEIN ISOTHIOCYANATE; HLA ANTIGEN; HLA B57 ANTIGEN; HLA B58 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3E12; UNCLASSIFIED DRUG;

ARTICLE; COHORT ANALYSIS; CRYOPRESERVATION; DNA FINGERPRINTING; DNA SEQUENCE; DRUG HYPERSENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPAIN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; FALSE POSITIVE REACTIONS; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; HIV-1; HLA-B ANTIGENS; HUMANS; TIME FACTORS;

EID: 84881471147     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1404-160     Document Type: Article

References (20)

1. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA Panel. JAMA. 2012; 308(4):387-402.
2. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLADR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002; 359:727-732. (Pubitemid 34215071)
3. Lucas A, Nolan D, Mallal S. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. J Antimicrob Chemother. 2007; 59(4):591-593. (Pubitemid 47073389)
4. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-HOM variant. Proc Natl Acad Sci USA. 2004; 101(12):4180-4185. (Pubitemid 38405903)
5. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics. 2004; 5(2):203-211. (Pubitemid 38351278)
6. Phillips EJ, Wong GA, Kaul R, et al. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS. 2005; 19(9):979-981. (Pubitemid 40834943)
7. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-B*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008; 46(7):1111-1118. (Pubitemid 351589880)
8. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008; 358(6):568-579.
9. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection 2008: Recommendations of the International AIDS Society-USA Panel. JAMA. 2008; 300(5):555-570.
10. Chui CK, Brumme ZL, Brumme CJ, et al. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Clin Infect Dis. 2007; 44(11): 1503-1508. (Pubitemid 46801597)
11. Waters LJ, Mackie NE, Pozniak A, Winston A. Polymorphisms at position 245 of HIV reverse transcriptase do not accurately predict the presence of human leukocyte antigen B*5701. Clin Infect Dis. 2007; 45(9):1243-1244. (Pubitemid 47580330)
12. Martin AM, Krueger R, Almeida CA, Nolan D, Phillips E, Mallal S. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome. Pharmacogenet Genomics. 2006; 16(5):353-357.
13. Airo P, Scarsi M, Malagoli A, et al. The convenience of fl ow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions. J Acquir Immune Defic Syndr. 2009; 51(3):361-362.
14. Kostenko L, Kjer-Nielsen L, Nicholson I, et al. Rapid screening for the detection of HLA-B57 and HLA-B58 in prevention of drug hypersensitivity. Tissue Antigens. 2011; 78(1):11-20.
15. Arrizabalaga J, Rodríguez-Alcántara F, Castañer JL, et al. Prevalence of HLA-B*5701 in HIV-infected patients in Spain (results of the EPI Study). HIV Clin Trials. 2009; 10(1):48-51.
16. Rodríguez-Sáinz C, Ramos R, Valor L, et al. Prognostic value of HIV-1 DNA in peripheral blood mononuclear cells for virological outcome in asymptomatic HIV-1 chronic infection. J Clin Virol. 2010; 48(3):168-172.
17. Valor L, Navarro J, Carbone J, et al. Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy. Vaccine. 2008; 26(22):2738-2745.
18. Goding JW. Monoclonal Antibodies: Principles and Practice. 3rd ed. San Diego: Academic Press, Harcourt Brace and Company; 1993.
19. Stevens R, Coates E, Street J, Cook E, Darke C. Comprehensive evaluation of two HLA-B17 monoclonal antibodies for fl ow cytometry-based HLA-B57/B58 screening prior to abacavir prescription [published online ahead of print December 26, 2012]. Int J Immunogenetics.
20. McMichel AJ, Parham P, Rust N, Brodsky F. A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17. Hum Immunol. 1980; 1: 121-129. (Pubitemid 12238821)